Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, 161 Fort Washington, New York, NY 10032, USA.
Transfus Apher Sci. 2022 Oct;61(5):103533. doi: 10.1016/j.transci.2022.103533. Epub 2022 Aug 29.
Sickle cell disease (SCD) is the most common inherited red blood cell (RBC) disorder worldwide, resulting in chronic hemolytic anemia, vaso-occlusion, tissue hypoxia, and ultimately end organ damage. The hallmark of the disease is manifested by vaso-occlusive crisis (VOC) resulting in acute on chronic pain, and the most common cause for presentation to the emergency department and hospital admission. The management of pain for patients with SCD in the U.S. has historically been socially and politically complex with most patients experiencing pain on a daily basis but not seeking immediate medical attention. The pathophysiology of acute and chronic pain in SCD is multifactorial and complex. Here, we describe factors contributing to acute and chronic pain in SCD and management strategies.
镰状细胞病（SCD）是全球最常见的遗传性红细胞（RBC）疾病，导致慢性溶血性贫血、血管阻塞、组织缺氧，最终导致终末器官损伤。该疾病的标志表现为血管阻塞危象（VOC）导致急性和慢性疼痛，是急诊和住院的最常见原因。美国 SCD 患者的疼痛管理在历史上具有社会和政治的复杂性，大多数患者每天都经历疼痛，但并不寻求立即就医。SCD 中急性和慢性疼痛的病理生理学是多因素和复杂的。在这里，我们描述了导致 SCD 中急性和慢性疼痛的因素和管理策略。
